GLUCOSE METABOLISM IN PROGRESSIVE NONFLUENT APHASIA WITH AND WITHOUT PARKINSONISM
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Progressive nonfluent aphasia (PNFA) is one of the language variants of frontotemporal dementia.1 Previously, PNFA, corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) were regarded as separate disease entities because of their distinctive clinical features and different anatomic involvement: left perisylvian area in PNFA,2 basal ganglia and dorsal midbrain in PSP, and perirolandic area in CBD.3 However, recent studies show that the 3 disorders share tauopathy and clinical features such as language disturbance and parkinsonism in common.4 Furthermore, one disorder even evolves into others along the course of disease progression.5
One of the typical examples of this evolution is that PNFA can develop into CBD or PSP.6 Therefore, we hypothesized that the topography of glucose hypometabolism in patients with PNFA with parkinsonism (PNFA+P) would differ from those without parkinsonism (PNFA-P), even before evolving into PSP or CBD. That is, PNFA+P would have more glucose hypometabolism in the basal ganglia, midbrain, or perirolandic areas that are known to be affected in PSP or CBD.
Methods.
Subjects.
We retrospectively found a total of 21 patients with PNFA who underwent clinical evaluations, including neuropsychological tests and [18F]fluoro-2-deoxy-d-glucose PET (FDG-PET) within a 3-month interval at a university-affiliated hospital. All patients fulfilled the diagnostic criteria for PNFA proposed …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSPK. A. Josephs, R. C. Petersen, D. S. Knopman et al.Neurology, January 09, 2006 -
Articles
Patterns of cortical thinning in the language variants of frontotemporal lobar degenerationJ. D. Rohrer, J. D. Warren, M. Modat et al.Neurology, May 04, 2009 -
Articles
Survival in frontotemporal dementiaJ.R. Hodges, R. Davies, J. Xuereb et al.Neurology, August 11, 2003 -
Article
Nonverbal oral apraxia in primary progressive aphasia and apraxia of speechHugo Botha, Joseph R. Duffy, Edythe A. Strand et al.Neurology, April 11, 2014